FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158655051> ?p ?o ?g. }

• W2158655051 endingPage "14" @default.
• W2158655051 startingPage "1" @default.
• W2158655051 abstract "Liver Transplantation and SurgeryVolume 4, Issue 1 p. 1-14 Original ArticleFree Access The mother lode of liver transplantation, with particular reference to our new journal Thomas E. Starzl, Corresponding Author Thomas E. Starzl MD,PhD. Pittsburgh Transplantation Institute University of Pittsburgh Medical Center, Pittsburgh, PA3601 Fifth Avenue, 4C Falk Clinic, Pittsburgh, PA 15213Search for more papers by this author Thomas E. Starzl, Corresponding Author Thomas E. Starzl MD,PhD. Pittsburgh Transplantation Institute University of Pittsburgh Medical Center, Pittsburgh, PA3601 Fifth Avenue, 4C Falk Clinic, Pittsburgh, PA 15213Search for more papers by this author First published: 30 December 2003 https://doi.org/10.1002/lt.500040101Citations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Welch CS, A note on transplantation of the whole liver in dogs. Transplant Bull 1955; 2: 54. 2 Goodrich EO, Welch HF, Nelson JA, Beecher TS, Welch CS. Homotransplantation of the canine liver. Surgery 1956; 39: 244– 252. 3 Starzl TE, Marchioro TL, Rowlands DT, Kirkpatrick CH, Wilson WEC, Rifkind D, Waddell WR. Immunosuppression after experimental and clinical homotransplantation of the liver. Ann Surg 1964; 160: 411– 439. 4 Starzl TE, Porter KA, Francavilla A. The Eck fistula in animals and humans. Curr Probl Surg 1983; 20: 687– 752.MEDLINE 5 Starzl TE, Kaupp HA, Brock DR, Lazarus RE, Johnson RV. Reconstructive problems in canine liver homotransplantation with special reference to the postoperative role of hepatic venous flow. Surg Gynecol Obstet 1960; 111: 733– 743. 6 Starzl TE, Halgrimson CG, Koep LJ, Weil R, Taylor PD. Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet 1979; 149: 737.MEDLINE 7 Shaw BW, Iwatsuki S, Bron K, Starzl TE. Portal vein grafts in hepatic transplantation. Surg Gynecol Obstet 1985; 161: 66– 68.MEDLINE 8 Sheil AGR, Thompson JF, Stevens MS, Eyers AA, Graham JC, Bookallil MJ. Mesoportal graft for thrombosed portal vein in liver transplantation. Clin Transplant 1987; 1: 18– 20. 9 Tzakis A, Todo S, Stieber A, Starzl TE. Venous jump grafts for liver transplantation in patients with portal vein thrombosis. Transplantation 1989; 48: 530– 531.MEDLINE 10 Bollman JL. The animal with an Eck fistula. Physiol Rev 1961; 41: 607– 621. 11 Starzl TE, Porter KA, Putnam CW. Intraportal insulin protects from the liver injury of portacaval shunt in dogs. Lancet 1975; 2: 1241– 1246.MEDLINE 12 Starzl TE, Watanabe K, Porter KA, Putnam CW. Effects of insulin, glucagon, and insulin/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet 1976; 1: 821– 825.MEDLINE 13 Child CG, Barr D, Holswade GR, Harrison CS. Liver regeneration following portacaval transposition in dogs. Ann Surg 1953; 138: 600– 608. 14 Fisher B, Russ C, Updegraff H, Fisher ER. Effect of increased hepatic blood flow upon liver regeneration. Arch Surg 1954; 69: 263– 272. 15 Marchioro TL, Porter KA, Dickinson TC, Faris TD, Starzl TE. Physiologic requirements for auxiliary liver homotransplantation. Surg Gynecol Obstet 1965; 121: 17– 31. 16 Marchioro TL, Porter KA, Brown BI, Otte J-B, Starzl TE. The effect of partial portacaval transposition on the canine liver. Surgery 1967; 61: 723– 732.MEDLINE 17 Starzl TE, Francavilla A, Halgrimson CG, Francavilla FR, Porter KA, Brown TH, Putnam CW. The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet 1973; 137: 179– 199.MEDLINE 18 Starzl TE, Porter KA, Kashiwagi N, Putnam CW. Portal hepatotrophic factors, diabetes mellitus and acute liver atrophy, hypertrophy and regeneration. Surg Gynecol Obstet 1975; 141: 843– 858.MEDLINE 19 Starzl TE, Porter KA, Kashiwagi N, Lee IY, Russell WJI, Putnam CW. The effect of diabetes mellitus on portal blood hepatotrophic factors in dogs. Surg Gynecol Obstet 1975; 140: 549– 562. 20 Starzl TE, Lee IY, Porter KA, Putnam CW. The influence of portal blood upon lipid metabolism in normal and diabetic dogs and baboons. Surg Gynecol Obstet 1975; 140: 381– 396. 21 Warren WD, Zeppa R, Fomon JJ. Selective transsplenic decompression of gastroesophageal varices by distal splenorenal shunt. Ann Surg 1967; 166: 437– 455.MEDLINE 22 Rikkers LF. Portal hemodynamics, intestinal absorption, and post-shunt encephalopathy. Surgery 1983; 94: 126– 133.MEDLINE 23 McDermott WV, Adams RD. Episodic stupor associated with an Eck fistula in the human with particular reference to the metabolism of ammonia. J Clin Invest 1954; 33: 1– 8. 24 Hubbard TB. Carcinoma of the head of the pancreas: resection of the portal vein and portacaval shunt. Ann Surg 1958; 147: 935– 944. 25 Putnam CW, Porter KA, Starzl TE. Hepatic encephalopathy and light electron micrographic changes of the baboon liver after portal diversion. Ann Surg 1976; 184: 155– 161.MEDLINE 26 Starzl TE, Chase HP, Putnam CW, Porter KA. Portacaval shunt in hyperlipoproteinemia. Lancet 1973; 2: 940– 944.MEDLINE 27 Rubin E, Gevirtz NR, Cohan P, Tomita F, Jacobson JH. Liver cell damage produced by portacaval shunt. Proc Soc Exp Biol Med 1965; 118: 235– 237. 28 Starzl TE, Jones AF, Terblanche J, Usui S, Porter KA, Mazzoni G. Growth-stimulating factor in regenerating canine liver. Lancet 1979; 1: 127– 130.MEDLINE 29 Mallet-Guy Y, Hezez G, Feroldi J. Anastomose portocave latero-laterale experimentale. Documents histologiques et electro-microscopiques. Lyon Chir 1972; 68: 436– 445.MEDLINE 30 Starzl TE, Marchioro TL, Sexton AW, Illingworth B, Waddell WR, Faris TD, Herrmann TJ. The effect of portacaval transposition on carbohydrate metabolism: experimental and clinical observations. Surgery 1965; 57: 687– 697. 31 Starzl TE, Putnam CW, Porter KA, Halgrimson CG, Corman J, Brown BI, et al. Portal diversion for the treatment of glycogen storage disease in humans. Ann Surg 1973; 178: 525– 539.MEDLINE 32 Starzl TE, Chase HP, Ahrens EH, McNamara DJ, Bilheimer DW, Schaefer EJ, et al. Portacaval shunt in patients with familial hypercholesterolemia. Ann Surg 1983; 198: 273– 283.MEDLINE 33 Starzl TE, Porter KA, Francavilla A, Iwatsuki S. Reversal of hepatic alpha-1-antitrypsin deposition after portacaval shunt. Lancet 1983; 2: 424– 426.MEDLINE 34 Starzl TE, Porter KA, Busuttil RW, Pichlmayr R. Portacaval shunt in 3 children with alpha-1-antitrypsin deficiency: 9 to 12 years later. Hepatology 1990; 11: 152– 154.MEDLINE 35 Hood JM, Koep LJ, Peters RL, Schroter GPJ, Weil R, Redeker AG, Starzl TE. Liver transplantation for advanced liver disease with alpha-1-antitrypsin deficiency. N Engl J Med 1980; 302: 272– 275.MEDLINE 36 Starzl TE, Bilheimer DW, Bahnson HT, Shaw BW, Hardesty RL, Griffith BP, Iwatsuki S, et al. Heart-liver transplantation in a patient with familial hypercholesterolemia. Lancet 1984; 1: 1382– 1383.MEDLINE 37 Malatack JJ, Finegold DN, Iwatsuki S, Shaw BW, Gartner JC, Zitelli BJ, et al. Liver transplantation for type I glycogen storage disease. Lancet 1983; 1: 1073– 1075.MEDLINE 38 Starzl TE, Demetris AJ, Van Thiel DH. Medical progress: liver transplantation. N Engl J Med 1989; 321: 1014– 1022.MEDLINE 39 Putnam CW, Porter KA, Peters RL, Ashcavai M, Redeker AG, Starzl TE. Liver replacement for alpha-1-antitrypsin deficiency. Surgery 1977; 81: 258– 261.MEDLINE 40 DuBois RS, Giles G, Rodgerson DO, Lilly J, Martineau G, Halgrimson CG, et al. Orthotopic liver transplantation for Wilson's disease. Lancet 1971; 1: 505– 508.MEDLINE 41 Groth CG, Dubois RS, Corman J, Gustafsson A, Iwatsuki S, Rodgerson DO, et al. Metabolic effects of hepatic replacement in Wilson's disease. Transplant Proc 1973; 5: 829– 833.MEDLINE 42 Brown I, Brown DH. Glycogen storage disease. In: F Dickens PJ Randle WJ Whelan eds. Carbohydrate metabolism and its disorders, New York: Academic. 1968; 2: 123– 150. 43 Kashiwagi N, Groth CG, Gecelter L, Amend JR, Blanchard H, Starzl TE. A DEAE cellulose batch technique for antilymphocyte globulin preparation. Surg Forum 1968; 19: 196– 198.MEDLINE 44 Alper CA, Johnson AM, Birtch AG, Moore FD. Human C3: evidence for the liver as the primary site of synthesis. Science 1969; 163: 286– 288.MEDLINE 45 Starzl TE. The little drummer girls. The puzzle people. ittsburgh, PA: University of Pittsburgh. 1992; 318– 333. 46 Goldstein J, Brown MS. Binding and degradation of low density lipoproteins in cultured human fibroblasts: comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem 1974; 249: 5153– 5162.MEDLINE 47 Goldstein JL, Kita T, Brown MS. Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N Engl J Med 1983; 309: 288– 296.MEDLINE 48 Shaw BW, Bahnson HT, Hardesty RL, Griffith BP, Starzl TE. Combined transplantation of the heart and liver. Ann Surg 1985; 202: 667– 672.MEDLINE 49 Starzl TE, Bilheimer DW, Bahnson HT, Shaw BW, Hardesty RL, Griffith BP, et al. Heart-liver transplantation in a patient with familial hypercholesterolemia. Lancet 1984; 1: 1382– 1383.MEDLINE 50 Bilheimer DW, Goldstein JL, Grundy SC, Starzl TE, Brown MS. Liver transplantation provides low-density-lipoprotein receptors and lowers plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 311: 1658– 1664.MEDLINE 51 Francavilla A, Hagiya M, Porter KA, Polimeno L, Ihara I, Starzl TE. Augmenter of liver regeneration (ALR): its place in the universe of hepatic growth factors. Hepatology 1994; 20: 747– 757.MEDLINE 52 Vujanovic NL, Polimeno L, Azzarone A, Francavilla A, Chambers WH, Starzl TE, et al. Changes of liver-resident natural killer cells during liver regeneration in rats. J Immunol 1995; 154: 6324– 6338.MEDLINE 53 Francavilla A, Vujanovic N, Polimeno L, Azzarone A, Iacobellis A, Deleo A, et al. The in vivo effect of hepatotrophic factors ALR, HGF, and IGF-II on natural killer cell functions. Hepatology 1997; 25: 411– 415.MEDLINE 54 LaBrecque DR, Pesch LA. Preparation and partial characterization of hepatic regenerative stimulator substance (HSS) from rat liver. J Physiol 1975; 248: 273– 284.MEDLINE 55 Terblanche J, Porter KA, Starzl TE, Moore J, Patzelt L, Hayashida N. Stimulation of hepatic regeneration after partial hepatectomy by infusion of a cytosol extract from regeneration dog liver. Surg Gynecol Obstet 1980; 151: 538– 544.MEDLINE 56 Hagiya M, Francavilla A, Polimeno L, Ihara I, Sakai H, Seki T, et al. Cloning and sequence analysis of the rat augmenter of liver regeneration (ALR) gene: expression of biologically active recombinant ALR and demonstration of tissue distribution. Proc Natl Acad Sci USA 1994; 91: 8142– 8146.MEDLINE 57 Lisowsky T. Dual function of a new nuclear gene for oxidative phosphorylation and vegetative growth in yeast. Mol Gen Genet 1992; 232: 58– 64.MEDLINE 58 Giorda R, Hagiya M, Seki T, Shimonishi M, Sakai H, Michaelson J, et al. Analysis of the structure and expression of the ALR gene. Mol Med 1996; 2: 97– 108.MEDLINE 59 McIndoe AH, Counseller VS. The bilaterality of the liver. Arch Surg 1927; 15: 589– 612. 60 Hjortsjo CH. The topography of the intrahepatic duct systems. Acta Anat 1950; 11: 599– 615. 61 Healey JE. Clinical anatomic aspects of radical hepatic surgery. J Int Coll Surg 1954; 22: 542– 550. 62 Healey JE, Schroy PC. Anatomy of the biliary ducts within the human liver. Arch Surg 1953; 66: 599– 616. 63 Couninaud C. Le foie. Les hepatectomies elargies. Etudes Anatomiques et Chirurgicales. Paris: Masson & Cie. 1957; 400– 409. 64 Goldsmith NA, Woodburne RT. The surgical anatomy pertaining to liver resection. Surg Gynecol Obstet 1957; 105: 310– 318. 65 Wangensteen OH. Cancer of the esophagus and stomach. Proceedings 3rd Natl. Cancer Conference. Philadelphia: Lippincott. 1951; 94– 97. 66 Lortat-Jacob JL, Robert HG. Hepatectomie droite reglee. Presse Med 1952; 60: 549– 551. 67 Quattlebaum JK. Massive resection of the liver. Ann Surg 1953; 137: 787– 796. 68 Pack GT, Miller TR, Brasfield RD. Total right hepatic lobectomy for cancer of the gallbladder. Ann Surg 1955; 142: 6. 69 Brunschwig A. The surgery of hepatic neoplasms with special reference to right and left lobectomies. XVI Congress de la Societe Internationale de Chirurgie, Copenhagen. Brussels: Imprimerie Medicale et Scientifique. 1955; 1122– 1132. 70 Pack GT, Molander DW. Metabolism before and after hepatic lobectomy for cancer. Arch Surg 1960; 80: 685. 71 Miller TR. Neoplasms of the liver. In: R Maingot eds. Abdominal operations, New York: Appleton-Century-Crofts. 1974: 2: 1226– 1246. 72 Starzl TE, Bell RH, Beart RW, Putnam CW. Hepatic trisegmentectomy or extended right lobectomy: relation to other liver resections. Surg Gynecol Obstet 1975; 141: 429– 438.MEDLINE 73 Starzl TE, Koep LJ, Weil R, Lilly JR, Putnam CW, Aldrete JA. Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet 1980; 150: 208– 214.MEDLINE 74 Starzl TE, Iwatsuki S, Shaw BW, Waterman PM, Van Thiel D, Diliz-P HS, et al. Left hepatic trisegmentectomy. Surg Gynecol Obstet 1982; 155: 21– 27.MEDLINE 75 Huguet C, Nordlinger B, Galopin JJ, Bloch P, Gallot D. Normothermic hepatic vascular exclusion for extensive hepatectomy. Surg Gynecol Obstet 1978; 147: 689– 693.MEDLINE 76 Strasberg SM. Terminology of liver anatomy and liver resections: coming to grips with hepatic babel. J Am Coll Surg 1997; 184: 413– 434.MEDLINE 77 Starzl TE. Late results and complications. Experience in hepatic transplantation. Philadelphia: Saunders. 1969; 348– 390. 78 Starzl TE, Penn I, Putnam CW, Groth CG, Halgrimson CG. Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy. Transplant Rev 1971; 7: 112– 145.MEDLINE 79 Calne RY, Rolles K, White DJG, Thiru S, Evans DB, McMaster P, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2: 1033– 1036.MEDLINE 80 Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984; 1: 583– 587.MEDLINE 81 Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, Lennette ET, Martinez OM, Krams SM, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524– 529.MEDLINE 82 Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723– 1728.MEDLINE 83 Dent PB, Peterson RDA, Good RA. The relationship between immunologic function and oncogenesis. In: RA Good D Bergsma eds. Immunologic deficiency diseases in man. New York: National Foundation Press. 1967; 443. 84 Page AR, Hansen AE, Good RA. Occurrence of leukemia and lymphoma in patients with agammaglobulinemia. Blood 1963; 21: 197– 206. 85 Klein G, Purtilo D. Summary: symposium on Epstein-Barr virus induced lymphoproliferative diseases in immunodeficient patients. Cancer Res 1981; 41: 4302– 4304.MEDLINE 86 Dolcetti R, Gloghini A, De Vita S, Vaccher E, De Re V, Tirelli U, et al. Characteristics of EBV-infected cells in HIV-related lymphadenopathy: implications for the pathogenesis of EBV-associated and EBV-unrelated lymphomas of HIV-seropositive individuals. Int J Cancer 1995; 63: 652– 659.MEDLINE 87 Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106– 112.MEDLINE 88 Frizzera G, Hanto DW, Gajl-Peczalska KJ, Rosai J, McKenna RW, Sibley RK, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262– 4279.MEDLINE 89 Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173– 192.MEDLINE 90 Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552– 565.MEDLINE 91 Marker SC, Ascher NL, Kalis JM, Simmons RL, Najarian JS, Balfour HH. Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients. Surgery 1979; 85: 433– 440.MEDLINE 92 Crawford DH, Thomas JA, Janossy G, Sweny P, Fernando ON, Moorhead JF, Thompson JH. Epstein- Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet 1980; 1: 1355– 1356.MEDLINE 93 Hanto DW, Frizzera G, Purtilo DT, Sakamoto K, Sullivan JL, Salmundsen AK, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981; 41: 4253– 4261.MEDLINE 94 Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of post transplant lymphoproliferative disorders. Curr Probl Surg 1988; 25: 367– 472.MEDLINE 95 Reyes J, Zeevi A, Ramos H, Tzakis A, Todo S, Demetris AJ, et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc 1993; 25: 3315– 3319.MEDLINE 96 Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet 1992; 339: 1579– 1582.MEDLINE 97 Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993; 17: 1127– 1152.MEDLINE 98 Starzl TE, Demetris AJ, Murase N, Trucco M, Thomson AW, Rao AS. The lost chord: microchimerism. Immunol Today 1996; 17: 577– 584.MEDLINE 99 Jaffe R, Trager JDK, Zeevi A, Sonmez-Alpan E, Duquesnoy R, Todo S, et al. Multivisceral intestinal transplantation: surgical pathology. Pediatr Pathol 1989; 9: 633– 654.MEDLINE 100 Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Post-transplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103: 748– 755.MEDLINE 101 Chadburn A, Suciu-Foca N, Cesarman E, Reed E, Michler RE, Knowles DM. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol 1995; 147: 1862– 1870.MEDLINE 102 Klein G. The Epstein-Barr virus and neoplasia. N Engl J Med 1975; 293: 1353– 1357.MEDLINE 103 Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 1994; 77: 791– 793.MEDLINE 104 Khanna R, Burrows SR, Moss DJ. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 1995; 59: 387– 405.MEDLINE 105 Masucci MG. Viral immunopathology of human tumors. Curr Opin Immunol 1993; 5: 693– 700.MEDLINE 106 Lacerda JF, Landanyi M, Louie DC, Fernandez JM, Papadopoulos EP, O'Reilly RJ. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 Scid/Scid mice. J Exp Med 1996; 183: 1215– 1228.MEDLINE 107 Pearson GR, Orr TW. Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens. JNCI 1976; 56: 485– 488. 108 Blazar B, Patarroyo M, Klein E, Klein G. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate. J Exp Med 1980; 151: 614– 627.MEDLINE 109 Lacerda JF, Ladanyi M, Jagiello C, O'Reilly RJ. Administration of rabbit anti-asialo GM1 antiserum facilitates the development of human Epstein-Barr virus–induced lymphoproliferations in xenografted C.B-17 Scid/Scid mice. Transplantation 1996; 61: 492– 497.MEDLINE 110 Picus J, Aldrich WR, Letvin NL. A naturally occurring bone-marrow-chimeric primate. I. Integrity of its immune system. Transplantation 1985; 39: 297– 303.MEDLINE 111 Picus J, Holley K, Aldrich WR, Griffin JD, Letvin NL. A naturally occurring bone marrow-chimeric primate. II. Environment dictates restriction on cytolytic T lymphocyte–target cell interactions. J Exp Med 1985; 162: 2035– 2052.MEDLINE 112 Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102: 400– 401. 113 Porter RP, Gengozian N. Immunological tolerance and rejection of skin allografts in the marmoset. Transplantation 1969; 8: 653– 665.MEDLINE 114 Cleary ML, Epstein MA, Finerty S, Dorfman RF, Bornkamm GW, Kirkwood JK, et al. Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science 1985; 228: 722– 724.MEDLINE 115 Miller G. In: MA Epstein, BG Achong (eds). Experimental carcinogenicity by the virus in vivo: The Epstein-Barr virus. New York: Springer. 1979; 351– 372. 116 Epstein MA. The Leeuwenhoek lecture, 1983. A prototype vaccine to prevent Epstein-Barr virus–associated tumours [Review]. Proc R Soc London 1984; 221: 1– 20. 117 Nelson BP, Nalesnik MA, Locker JD, Bahler DW, Swerdlow SH. EBV negative posttransplant lymphoproliferative disorders: a distinct entity? Lab Invest 1996; 74: 118A. 118 Nalesnik MA, Rao AS, Furukawa H, Pham S, Zeevi A, Fung JJ, et al. Autologous lymphokine-activated killer (LAK) cell therapy of EBV+ and EBV− lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997; 63: 1200– 1205.MEDLINE 119 Hanto DW, Gajl-Peczalska KJ, Frizzera G, Arthur DC, Balfour HH, McClain K, et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg 1983; 198: 356– 369.MEDLINE 120 Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97: 14– 24.MEDLINE 121 Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333– 3340.MEDLINE 122 Chen JM, Barr ML, Chadburn A, Frizzera G, Schenkel FA, Sciacca RR, et al. Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 1993; 56: 527– 538.MEDLINE 123 Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabase MH, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185– 1191.MEDLINE 124 Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus–related lymphoproliferation. Lancet 1995; 345: 9– 13.MEDLINE 125 Emanuel DJ, Lucas KG, Mallory GB, Edwardsbrown MK, Pollok KE, Conrad PD, et al. Treatment of post-transplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 1997; 63: 1691– 1694.MEDLINE 126 Wilson AD, Shooshstari M, Finerty S, Watkins P, Morgan AJ. Virus-specific cytotoxic T cell responses are associated with immunity of the cottontop tamarin to Epstein-Barr virus (EBV). Clin Exp Immunol 1996; 103: 199– 205.MEDLINE 127 Morgan AJ, Mackett M, Finerty S, Arrand JR, Scullion FT, Epstein MA. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J Med Virol 1988; 25: 189– 195.MEDLINE 128 Epstein MA, Randle BJ, Finerty S, Kirkwood JK. Not all potently neutralizing, vaccine induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clin Exp Immunol 1986; 63: 485– 490.MEDLINE 129 Todo S, Reyes J, Furukawa H, Abu-Elmagd K, Lee RG, Tzakis A, et al. Outcome analysis of 71 clinical intestinal transplantations. Ann Surg 1995; 222: 270– 282.MEDLINE 130 Coggin JH, Larson VM, Hilleman MR. Prevention of SV40 virus tumorigenesis by irradiated, disrupted and iododeoxyuridine treated tumor cell antigens. Proceedings of the Society for Experimental Biology and Medicine 1967; 124: 774– 784.MEDLINE 131 Goldner H, Girardi AJ, Larson VM, Hilleman MR. Interruption of SV40 virus tumorigenesis using irradiated homologous tumor antigen. Proc Soc Exp Biol Med 1964; 117: 851– 857. 132 Starzl TE, Klintmalm GBG, Porter KA, Iwatsuki S, Schroter GPJ. Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 1981; 305: 266– 269.MEDLINE 133 Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain A. FK 506 for human liver, kidney and pancreas transplantation. Lancet 1989; 2: 1000– 1004.MEDLINE 134 Fung JJ, Todo S, Jain A, McCauley J, Alessiani M, Scotti C, Starzl TE. Conversion of liver allograft recipients with cyclosporine related complications from cyclosporine to FK 506. Transplant Proc 1990; 22: 6– 12.MEDLINE 135 Todo S, Fung JJ, Starzl TE, Tzakis A, Demetris AJ, Kormos R, et al. Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 1990; 212: 295– 305.MEDLINE 136 Todo S, Reyes J, Furukawa H, Abu-Elmagd K, Lee RG, Tzakis A, et al. Outcome of intestinal transplantation. Ann Surg 1995; 222: 270– 282.MEDLINE 137 Randomised trial comparing tacrolimus (FK 506) and cyclosporin in prevention of liver allograft rejection. European FK 506 Multicentre Liver Study Group (Neuhaus P, Pichlmayr R, Williams R). Lancet 1994; 344: 423– 428.MEDLINE 138 A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. US Multicenter FK 506 Liver Study Group (Klintmalm G). N Engl J Med 1994; 331: 1110– 1115.MEDLINE 139 Starzl TE, Donner A, Eliasziw M, Stitt L, Meier P, Fung JJ, et al. Randomized trialomania? The multicenter liver transplant trials. Lancet 1995; 346: 1346– 1350.MEDLINE 140 Fung JJ, Todo S, Jain A, Demetris AJ, McMichael JP, Starzl TE. The Pittsburgh randomized trial of tacrolimus versus cyclosporine for liver transplantation. J Am Coll Surg 1996; 183: 117– 125.MEDLINE Citing Literature Volume4, Issue1January 1998Pages 1-14 ReferencesRelatedInformation" @default.
• W2158655051 created "2016-06-24" @default.
• W2158655051 creator A5081289232 @default.
• W2158655051 date "1998-01-01" @default.
• W2158655051 modified "2023-09-24" @default.
• W2158655051 title "The mother lode of liver transplantation, with particular reference to our new journal" @default.
• W2158655051 cites W1207597138 @default.
• W2158655051 cites W1458946433 @default.
• W2158655051 cites W1485806819 @default.
• W2158655051 cites W1503584616 @default.
• W2158655051 cites W154895026 @default.
• W2158655051 cites W1553271305 @default.
• W2158655051 cites W1571321875 @default.
• W2158655051 cites W157199325 @default.
• W2158655051 cites W161335516 @default.
• W2158655051 cites W1667518891 @default.
• W2158655051 cites W1737343460 @default.
• W2158655051 cites W1738779651 @default.
• W2158655051 cites W1820009634 @default.
• W2158655051 cites W1855945624 @default.
• W2158655051 cites W1874138720 @default.
• W2158655051 cites W1908565253 @default.
• W2158655051 cites W1917383401 @default.
• W2158655051 cites W1968073978 @default.
• W2158655051 cites W1968633192 @default.
• W2158655051 cites W196981708 @default.
• W2158655051 cites W1970198698 @default.
• W2158655051 cites W1971381771 @default.
• W2158655051 cites W1972308391 @default.
• W2158655051 cites W1977635228 @default.
• W2158655051 cites W1982766793 @default.
• W2158655051 cites W1985021283 @default.
• W2158655051 cites W1985342798 @default.
• W2158655051 cites W1986819764 @default.
• W2158655051 cites W1987377262 @default.
• W2158655051 cites W1987747179 @default.
• W2158655051 cites W1989036548 @default.
• W2158655051 cites W1992520824 @default.
• W2158655051 cites W1992891702 @default.
• W2158655051 cites W1993241807 @default.
• W2158655051 cites W1993585619 @default.
• W2158655051 cites W1994519312 @default.
• W2158655051 cites W1998855821 @default.
• W2158655051 cites W2001104440 @default.
• W2158655051 cites W2001487852 @default.
• W2158655051 cites W2001891755 @default.
• W2158655051 cites W2004754125 @default.
• W2158655051 cites W2004916841 @default.
• W2158655051 cites W2009179278 @default.
• W2158655051 cites W2013971858 @default.
• W2158655051 cites W2015965040 @default.
• W2158655051 cites W2017308991 @default.
• W2158655051 cites W2021784109 @default.
• W2158655051 cites W2022350058 @default.
• W2158655051 cites W2025123467 @default.
• W2158655051 cites W2033329689 @default.
• W2158655051 cites W2034683890 @default.
• W2158655051 cites W2039801541 @default.
• W2158655051 cites W2042690900 @default.
• W2158655051 cites W2050069240 @default.
• W2158655051 cites W2051742401 @default.
• W2158655051 cites W2053655009 @default.
• W2158655051 cites W2055041361 @default.
• W2158655051 cites W2055121411 @default.
• W2158655051 cites W2057347205 @default.
• W2158655051 cites W205753852 @default.
• W2158655051 cites W2060949011 @default.
• W2158655051 cites W2062870849 @default.
• W2158655051 cites W2064677611 @default.
• W2158655051 cites W2065273713 @default.
• W2158655051 cites W2067869320 @default.
• W2158655051 cites W2072664672 @default.
• W2158655051 cites W2074261174 @default.
• W2158655051 cites W2078689597 @default.
• W2158655051 cites W2080062050 @default.
• W2158655051 cites W2085750936 @default.
• W2158655051 cites W2086135210 @default.
• W2158655051 cites W2087945339 @default.
• W2158655051 cites W2090260209 @default.
• W2158655051 cites W2090832620 @default.
• W2158655051 cites W2111038396 @default.
• W2158655051 cites W2112016055 @default.
• W2158655051 cites W2112276914 @default.
• W2158655051 cites W2115173524 @default.
• W2158655051 cites W2115598881 @default.
• W2158655051 cites W2117007634 @default.
• W2158655051 cites W2117072316 @default.
• W2158655051 cites W2119322483 @default.
• W2158655051 cites W2126953074 @default.
• W2158655051 cites W2127138371 @default.
• W2158655051 cites W2127450135 @default.
• W2158655051 cites W2128530289 @default.
• W2158655051 cites W2132243512 @default.
• W2158655051 cites W2137858837 @default.
• W2158655051 cites W2141768093 @default.
• W2158655051 cites W2141835142 @default.
• W2158655051 cites W2146722250 @default.
• W2158655051 cites W2152726242 @default.

• next